India's Biotech Department Steps In To Boost Biosimilars Programs Of Indian Companies
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Realizing the importance of developing inexpensive biotech treatments, India's Department of Biotechnology has for the first time invited proposals from Indian companies to work together on the development of biosimilar products
You may also be interested in...
Lack Of Risk Funding Impedes India's Discovery R&D Growth But Mindset Change Is Making A Difference, Report Says
MUMBAI - Acute shortage of risk funding is turning to be a significant impediment for development of innovative companies in India, especially for start-ups looking to scale their operations or invest in new R&D technologies, the latest report titled Financing Ecosystem of the Indian Life Science Industry by investment bank Yes Bank and industry lobby Confederation of Indian Industry noted
Lack Of Risk Funding Impedes India's Discovery R&D Growth But Mindset Change Is Making A Difference, Report Says
MUMBAI - Acute shortage of risk funding is turning to be a significant impediment for development of innovative companies in India, especially for start-ups looking to scale their operations or invest in new R&D technologies, the latest report titled Financing Ecosystem of the Indian Life Science Industry by investment bank Yes Bank and industry lobby Confederation of Indian Industry noted
Launch Delays In U.S. Dampen Dr. Reddy's Q1 Earnings But Money Starts Flowing From GSK Deal; Analysts Confident On Future Outlook
MUMBAI - The first tangible benefits of the deal Dr. Reddy's Labs struck last year with GlaxoSmithKline for supply of over 100 branded formulations have become visible with the Indian company receiving $4 million from its British partner in return for moving dossiers and trademarks for nine currently marketed products in Brazil